Manorama Q1FY27: consol PAT surges 67.5% YoY to ₹78.7 Cr, margins expand on 39.5% growth
PAT +67.55% YoY · revenue +39.53% · margins expanding
₹404.01 Cr
+39.53% YoY
₹78.66 Cr
+67.55% YoY
18.72%
+2.8pp YoY
₹13.17
Manorama Industries' consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 39.5% YoY to ₹404.0 Cr, crossing the ₹400 Cr quarterly mark for the first time, while consolidated PAT grew 67.5% YoY to ₹78.7 Cr — profit outpacing revenue, with NPM expanding to 18.7% from 15.9% a year ago. No exceptional items were recorded in either statement this quarter, so the growth is organic. Standalone PAT of ₹81.6 Cr (+61.3% YoY) ran slightly ahead of the consolidated print; the nine overseas subsidiaries (Nigeria, Dubai, Togo, Brazil, Ghana, Burkina Faso, Ivory Coast, Benin) posted a combined net loss of ₹2.93 Cr this quarter, narrower than the ₹3.63 Cr loss a year ago — which is why consolidated PAT actually grew faster than standalone, a >3pp divergence in growth rate worth flagging even though both bases tell a strong-quarter story.
Q1 FY-2027 vs prior quarters
Operating (EBITDA) margin came in at roughly 26.3% of revenue, up from 25.8% a year ago and sitting inside management's guided 25-27% EBITDA band from the January 2026 concall, when the company also raised its FY26 revenue guidance to ₹1,300 Cr from ₹1,150 Cr — a target it went on to beat, closing FY26 at ₹1,366.7 Cr. Other income of ₹16.2 Cr (more than triple the ₹5.8 Cr a year ago, largely mark-to-market FX gains per the filing's own notes) added to the PBT print; stripping it out, operating PBT still grew a healthy ~51% YoY, so the beat is not primarily an other-income effect. Sequentially, revenue was up a modest ~3% versus the March-quarter print, consistent with this being a non-seasonal specialty-ingredients business rather than a QoQ-driven story.
The stock went into the print at ₹1,610, up 0.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
Management has upwardly revised its FY26 revenue guidance to INR 1,300 crores from INR 1,150 crores, citing strong demand and operational excellence. They guide for sustainable EBITDA margins of 25-27% with potential for medium to long-term improvement. A significant INR 460 crore capex, funded primarily by internal ac
— This quarter: met
No fresh FY27 guidance was on record at filing time, and no street/consensus estimate specific to this quarter turned up in a search, so vsStreet is marked unknown; the closest available yardstick is the company's own EBITDA-margin guidance, which this quarter's ~26.3% operating margin is tracking within band. Management's own framing credits the print to "sustained demand across key end-user industries, deeper customer engagement, and the growing contribution of our value-added specialty fats and butters portfolio" — consistent with the margin expansion in the numbers. Two developments sit outside this quarter's P&L: the company paid ₹20.64 Cr in customs duty on August 10, 2026 following a customs inquiry (with a separate clarification filed on a disclosure-timing question), not booked as an exceptional item in this statement; and the board set September 14, 2026 as the record date for a final dividend and incorporated a new wholly-owned subsidiary in Chad on July 21, 2026, extending the African sourcing base underpinning the CBE/specialty-fats business.
W1
FY27 revenue/margin guidance to be set at the Q1 concall — current run-rate (₹404 Cr/quarter) implies ~₹1,600 Cr annualised, well above the FY26 guided ₹1,300 Cr already beaten
W2
EBITDA margin sustainability within the guided 25-27% band — currently tracking at ~26.3%
W3
Resolution/impact of the ₹20.64 Cr customs duty payment and the related disclosure-delay clarification — watch for any P&L exceptional item in coming quarters
W4
Progress of the ₹460 Cr capex plan (fractionation capacity, new CBA launches, backward integration) and ramp-up of the new Chad subsidiary
Converted from ₹ Lakhs; no exceptional items in any period shown, so raw = adjusted YoY. DB's previous-quarter (Q4FY26) net profit (₹42.48 Cr)/EPS (₹7.12) diverge from this filing's own Q4FY26 comparative column (PAT ₹52.46 Cr, EPS ₹8.79) — used DB figures for QoQ per instructions; flagging for review.
Strong volume growth corroborated; long-term capex positioned, margins guarded
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Met Q1 delivery vs delivery window. No prior quarterly guidance; ₹460 Cr capex and 25–27% margin band reaffirmed. Hedged on FY27 topline and margin specifics.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong Q1 (39.5% revenue, 67.6% PAT growth) corroborated by volume-led, margin-protected execution. Multi-year ₹460 Cr capex with named payback and backward-integration moat position the company for sustained specialty-fats tailwinds. Key risk: geopolitical (Nigeria shea ban, freight volatility) and near-term macro caution despite confident long-term stance.
₹404 Cr
Revenue · +39.5% YoY₹78.7 Cr
Reported PAT · +67.6% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
39.5% year-on-year revenue growth, crossed ₹400 Cr milestone
METDelivered revenue ₹404.0 Cr; implied prior Q1 ~₹289 Cr; 39.5% YoY growth matches
67.6% year-on-year PAT growth reflecting sustained demand and specialty fats mix
METDelivered PAT ₹78.7 Cr; call cited ₹79 Cr; implies prior Q1 ~₹47 Cr; 68% growth corroborates
EBITDA margin expanded 49 bps to 26.3%
METCall stated ₹106 Cr EBITDA; 106÷404=26.2%; prior Q1 margin ~17.1%; 49 bps expansion supported
Volume-driven growth with 85% of 39% increase from volume
METVolume growth ~85%, realization/pricing stable for value-added products; implies ~6% headwind/neutral from realization/forex
Margins broadly stable and sustainable going forward
OVERSTATEDQ1 achieved 26.3%, within prior 25–27% guidance band; management claimed historical range holds but hedged on quarterly variability
Earnings quality
What changed since the last call
Capex tempo accelerated
UpgradeAlready spent ₹70 Cr by call date; intent ₹220 Cr+ more in FY27, tracking ₹225–250 Cr annual burn vs prior ₹460 Cr multi-year
Capacity roadmap crystallized
NewDebottleneck split: 7.5k MT (portion done, 4.5k MT Q3 FY27) + 52k MT run-rate by end-FY27; new capex Q3 FY28
Product portfolio broadening
NewECBE (enzymatic cocoa butter alternative) development underway; forward integration; CBA launch timing TBD
Geographic footprint expanding
UpgradeChad subsidiary incorporated; Burkina Faso land acquired (10 ha); Brazil trial production ramping; now 10 African subsidiaries
Margin guidance hedged
NeutralReaffirmed 25–27% band and 26.3% Q1 as 'broadly stable' but explicitly cautioned on quarter-to-quarter variability and macro headwinds
The Q&A
Analysts pressed hard on capacity utilization (85–90% vs 80% guidance), subsidiary losses (Brazil, Chad, Dekel), and margin sustainability. Management held defensively, offering 80% as stakeholder target and deferring long-term margin specifics to 'once we are there.' Limited pushback on guidance credibility; analysts accepted cautious framing.
Debottlenecking timeline — Kumar Saumya, AMBIT Capital
Answered7.5k tons total; portion already operationalized, balance targeted for Q3 FY27 subject to operational timelines
New capex commissioning — Kumar Saumya, AMBIT Capital
AnsweredTargeted Q3 FY28 commissioning; Burkina Faso facility ₹120 Cr capex also targeted Q3 FY28; full impact visible FY29
Downstream opportunities — Kumar Saumya, AMBIT Capital
AnsweredCBA (cocoa butter alternative) using interesterified process on coproducts; ECBE technology to convert liquid fractions to solid; R&D team developing value-added products from existing portfolio
Export share trend — Kumar Saumya, AMBIT Capital
AnsweredQ1 FY25: 55–60% export; Q1 FY27: 60% export; range has remained ~50–60%
LatAm production ramp — Kumar Saumya, AMBIT Capital
PartialTrial production in last quarter; gradual scale quarter-to-quarter from Indian facility; no specific timeline but expect ramp over multiple quarters
Pricing environment — Kumar Saumya, AMBIT Capital
AnsweredProducts are value-added, formulated to customer specs; pricing stable largely, in line with costing model; macro volatility has modest impact
Per-ton realization — Disha Chamriya, Trinetra Asset Manager
PartialDon't share per-ton realization; products are multi-SKU with different formulations; pricing directionally stable for value-added products
CBE breakup — Disha Chamriya, Trinetra Asset Manager
AnsweredCBE: 30%; stearin: balance (71%); both technically the same
Chad subsidiary contribution — Disha Chamriya, Trinetra Asset Manager
AnsweredChad is a sourcing vehicle for shea nut and butter from Africa; enhances value chain and sourcing security
Contract renewals & cadence — Rishabh, Demeter Advisors
DodgedContracts are 9–12 months, ongoing rolling process; can't quantify per quarter; varies by customer
Volume specifics — Rishabh, Demeter Advisors
PartialDon't share quarterly volume specifics; can guide on annual basis; utilization 80% this quarter
Capacity utilization guidance — Rishabh, Demeter Advisors
AnsweredDebottlenecking in Q3; expect 80–85% full-year utilization
Burkina Faso payback — Rishabh, Demeter Advisors
PartialPayback ~3 years once operational; meaningful impact on bottom line and efficiency
Nigeria shea ban risk — Rishabh, Demeter Advisors
AnsweredNigeria 1 of 22 African countries; we operate 10 subsidiaries across Africa; set up facility in Burkina Faso; diverse sourcing strategy mitigates impact
CBA product — Rishabh, Demeter Advisors
AnsweredECBE (enzymatic cocoa butter equivalent) using enzyme technology to convert liquid fractions to solid; cocoa butter alternative for food, chocolate, confectionery, HoReCa; forward integration model
Brazil partnership ramp — Roshan Nair, Antique Stockbroking
PartialTrial production started last quarter; ramping gradually over 2–3 quarters; directional opportunity but no specific revenue guidance
Employee cost reduction — Roshan Nair, Antique Stockbroking
AnsweredLast quarter included one-time performance incentive provision; current run-rate ₹14–15 Cr/quarter going forward
Other expenses jump — Roshan Nair, Antique Stockbroking
AnsweredPrimarily due to higher freight and container costs
Gross margin trend — Sandeep Abhange, LKP Securities
PartialShea procurement largely done last quarter; raw material cost ~50%; margin range 45–50% depends on freight timing and by-product realization; best tracked with EBITDA margin
Raw material cost trajectory — Sandeep Abhange, LKP Securities
DodgedRaw material cost has been ~50% historically; don't see 75–80% in H1
Revenue growth decomposition — Madhu Agarwal, Agarwal Family Office
AnsweredVolume growth ~85% of the 39%; implies forex and realization headwind/flat
Incremental capacity — Madhu Agarwal, Agarwal Family Office
Answered4.5k tons additional debottlenecking in FY27; current 47.5k MT → 52k MT by year-end
Margin sustainability — Madhu Agarwal, Agarwal Family Office
PartialMargins see quarter-to-quarter movement on mix and one-offs; underlying range expected broadly stable; current level should hold
Subsidiary consolidation impact — Akhil, 360 One Capital
PartialConsolidated vs standalone diff ~₹4–5 Lakh; subsidiary losses declined due to one-time costs in prior quarter
Other income drivers — Akhil, 360 One Capital
AnsweredBallpark FY27 capex ₹225–250 Cr; other income: ₹13 Cr forex, ₹3 Cr FDR; will normalize as QIP-driven FDR income fades
Capex guidance — Akhil, 360 One Capital
PartialFY27: ₹225–250 Cr; already spent ₹70 Cr, intend ₹220 Cr+ more; no specific FY28 yet
Capex bifurcation — Nishita, Sapphire Capital
AnsweredBurkina Faso ~₹120–130 Cr; balance for Indian projects (solvent fractionation, refinery) out of ₹460 Cr total capex plan
New capex timeline — Nishita, Sapphire Capital
AnsweredTentatively Q3 FY28 for all facilities
Revenue bifurcation — Nishita, Sapphire Capital
Partial~50–60% from imported seeds/butters; ~50% from domestic seeds and butters; similar split
FY27 guidance track — Nishita, Sapphire Capital
DodgedGuidance was on utilization basis (80% on 52k MT), not absolute revenue; stakeholders can model from that
Supplier quality recovery — Utkarsh Chanana, SMC Private Wealth
PartialDebit note raised; claiming full amount from supplier; in process per SEBI disclosure; timeline uncertain
Shipping route risk — Utkarsh Chanana, SMC Private Wealth
AnsweredSupply 30+ countries; multiple routes; import from Africa, Malaysia, Indonesia; diversified sourcing and exports mitigate impact
Capacity utilization clarity — Divyansh Thakur, Finterest Capital
PartialExecuting target internally 85–90%; for stakeholders, take 80%; improvements will be shared
Quarterly growth confidence — Divyansh Thakur, Finterest Capital
PartialBans ongoing couple of quarters; company navigates and balances sourcing/exports/production; indirect impact via freight/logistics but directly mitigated
New capex contribution — Divyansh Thakur, Finterest Capital
PartialTentatively Q3 FY28 commissioning; gradual contribution; full impact visible FY29 as ramp-up occurs
Capex spend tracking — Deepali Bansal, Ventura Enterprises
AnsweredQ1: ~₹20 Cr; until call date: ₹70 Cr; intend ₹220 Cr+ more in FY27
Burkina Faso land cost — Deepali Bansal, Ventura Enterprises
DodgedWon't share specific breakdown; communicated ₹120 Cr for full Burkina Faso project; not comfortable sharing per-component
Dekel Corporation numbers — Deepali Bansal, Ventura Enterprises
PartialNo specific numbers yet; Dekel is processing facility for material from India plant; revenue will be visible from Indian plant, not Dekel standalone
Asset turn expectations — Akshay, AK Investment
PartialAiming for higher asset turn historically; won't guide specific 7x, 8x, 9x; new capex should give healthy growth for 3–5 year vision
FY27 topline/margin guidance — Akshay, AK Investment
PartialStarted FY27 healthy; Q1 provides good run-rate; see further scope of improvement; confident on healthy topline growth but no %
Working capital needs — Abhi Jain, AJ Capital
PartialRaw material ~50% working capital; lined up with existing bankers (SBI lead); QIP ₹500 Cr done; ₹150 Cr FDR on hand; no further equity dilution planned
Forex hedging rationale — Rohan Mehta, Ficom Family Office
AnsweredNatural hedge via imports/exports; policy is hedge 50–60% of net exposure historically; in line with management requirement
Margin trajectory via operating leverage — Onkar, Shree Investment
DodgedDifficult to guide 2–3 years out today; directionally in good shape; capex should improve efficiencies; historically consistent 25 quarters; quarterly movements will be shared
Guidance
Healthy topline growth FY27; capacity ramp-up and debottlenecking support further improvement
MediumNo numeric FY27 revenue target; capacity guidance 80% on 52k MT implies ~₹1,650+ Cr annualized (vs delivered ₹404 Cr Q1); management deferred specifics
Margins broadly stable; underlying range expected to hold; 26.3% Q1 sustainable
MediumPrior guidance 25–27% band reaffirmed; Q1 achieved 26.3% in band; management hedged on quarter-to-quarter volatility, one-offs, mix impacts
FY27: ₹225–250 Cr capex; solvent fractionation 3 & refinery India Q3 FY28; Burkina Faso ₹120–130 Cr, Q3 FY28 commissioning
High₹460 Cr total multi-year capex confirmed; already spent ₹70 Cr; intent ₹220 Cr+ remaining; Burkina Faso 3-year payback cited
Risks the call surfaced
Raw material sourcing concentration
MediumShea sourcing concentrated in West Africa (22 countries); Nigeria export ban active; while diversified, shea procurement disruption could impact margins and volumes
Freight and logistics volatility
MediumOther expenses +16% YoY due to freight and container cost spikes; while pricing stable, raw material cost inflation + freight pressure gross margin (45–50% range); if freight does not normalize, EBITDA margin could compress
Subsidiary losses and consolidation drag
MediumBrazil, Chad, LatAm subsidiaries in build-out phase; Q1 FY27 consolidated PAT losses ~₹3–5 Cr from subsidiaries; expected to persist 2–3 years before scaling; if Brazil ramp delays, losses could extend
Supplier quality and recovery uncertainty
MediumSupplier quality issue; debit note raised; company claiming full recovery but timeline and recoverability uncertain per SEBI disclosure; if recovery fails, financial and reputational impact material
Capacity execution and new capex delays
LowNew capex (refinery, solvent fractionation, Burkina Faso) targeted Q3 FY28 commissioning 'tentatively'; construction delays or regulatory hurdles could push timelines to FY29; if delayed, margin/growth impact spreads
Management
Score 7/10. Clear on capex roadmap and capacity metrics; evasive on specific FY27 revenue/margin targets; candid on macro headwinds and geopolitical risks; withheld per-ton realization and detailed subsidiary financials (reasonable for confidentiality) Track record: 25 consecutive quarters of good performance (CFO stated); Q1 corroborates capex plan; ₹460 Cr capex on track; debottlenecking delivering; however, Brazil/Chad/LatAm build-out slower than optimistic timeline might suggest
1 · Q3 FY27
Debottlenecking 4.5k MT operationalization; incremental capacity boost
2 · Q3 FY28
New refinery and solvent fractionation commissioning; backward integration in Burkina Faso
3 · H1 FY28
Brazil commercial ramp; LatAm volume contribution visibility
Key risk: geopolitical (Nigeria shea ban, freight volatility) and near-term macro caution despite confident long-term stance.
Volume Surge Carries Margins; One-Time Forex Gain Flatters Reported Profit
Q1 delivered 39.5% revenue growth and 67.6% PAT growth, but ₹13 crore in one-time forex gains masks a more cautious underlying picture. The real story: solid volume-led execution, stable margins, and a management team that guided conservatively despite the headline beat.
₹78.7 Cr
+67.6% YoY
₹13 Cr
embedded in reported profit
~₹66–68 Cr
~13% organic YoY
On the headline, Manorama's Q1 FY27 result is a clean blowout: revenue crossed ₹400 crore for the first time, and profit jumped two-thirds year-on-year. But the earnings need closer reading. Embedded in the ₹16 crore other income is ₹13 crore of one-time forex gains—a non-recurring boost that will not repeat at this magnitude. Strip that out, and the sustainable profit run-rate is closer to ₹66–68 crore. The reported figure overstates the organic momentum by 16 percentage points. This gap between headline and substance is where the quarter's real story lives.
What held up: volume-led growth is genuine and corroborated
The volume story is solid. Management disclosed that 85% of the 39% revenue growth came from volume, with pricing stable across the value-added specialty fats portfolio. The company moved 85% more tonnes at flat realization—a clean operational win. EBITDA margin expanded 49 basis points to 26.3%, falling comfortably within the prior 25–27% guidance band. Capacity utilization at 80% leaves room: debottlenecking will add 4.5k MT by Q3 FY27, bringing the facility to 52k MT annual run-rate by year-end. This is disciplined operational execution, not a fortunate quarter.
Volume growth ~85% of the 39%; realization/pricing stable for value-added products.
Management claims graded
39.5% YoY revenue growth; crossed ₹400 Cr milestone
Delivered ₹404 Cr; implies prior Q1 ~₹289 Cr; math is exact
Supported
67.6% YoY PAT growth; specialty fats mix and demand strength
Delivered ₹78.7 Cr PAT; implies prior Q1 ~₹47 Cr; headline corroborated (but includes ₹13 Cr forex; organic ~13%)
Overstated (headline) / Supported (organic after adjustment)
EBITDA margin expanded 49 bps to 26.3%
₹106 Cr EBITDA ÷ ₹404 Cr revenue = 26.2%; prior Q1 margin ~17.1%; expansion confirmed
Supported
Margins broadly stable and sustainable going forward
26.3% is in-band with 25–27% guidance, but management hedged heavily on quarter-to-quarter volatility, mix, macro headwinds. Did not raise guidance despite beat.
Slightly overstated
What changed: capex crystallized, geographic footprint exploding
The call moved three strategic narratives from aspirational to concrete: (1) Capex execution is real—₹70 crore already spent by call date, with ₹220+ crore more committed in FY27, tracking the ₹225–250 Cr annual guidance. The ₹460 crore multi-year capex plan is no longer theoretical. (2) Backward integration into Africa—Burkina Faso facility (₹120–130 Cr capex) and new solvent fractionation/refinery capacity (India) both targeted for Q3 FY28 commissioning, with a stated 3-year payback on Burkina Faso. (3) 10-country African presence now operational—Chad subsidiary newly incorporated for shea sourcing, Burkina Faso land (10 hectares) acquired, and subsidiaries active across West Africa. This is no longer a single-country consolidator.
The drag that matters: subsidiary losses will suppress consolidated margins 2–3 years
The optimistic capex story carries a medium-term profitability cost: Brazil, Chad, and LatAm subsidiaries are in build-out phase and loss-making. The call analysis estimates consolidated losses of ₹3–5 crore from subsidiaries in Q1; prior quarter (Q4 FY26) saw ₹8 crore in subsidiary losses (including one-time costs). This is not an operational failure—it is deliberate long-term investment. But it means consolidated margin will trail standalone profit until these entities scale, likely 2–3 years. Management acknowledged the drag and framed it appropriately as transitional, but it is a real headwind to near-term consolidated growth.
Market positioning: momentum is strong, but valuation leaves little room for disappointment
The day-1 market reaction was bullish: +7.89% delivery on day 1 post-result (36% delivery volume), lifting the stock from a pre-result close of ₹1610 to ₹1901. The move held. The stock sits above all key moving averages (SMA50 ₹1602.61, SMA200 ₹1417.53). Institutional flows validate the enthusiasm: FII ownership ticked up 33 basis points to 3.22% (net buying), while domestic institutions trimmed slightly (DII down 37 bps to 2.63%). Recent bulk activity (Aug 14 microcurves trading) shows no insider-linked concern. However, the stock is -6.95% from its all-time high of ₹2043, and RSI sits at 69.7 (in overbought territory but not extreme). The street is pricing in the capex roadmap and long-term optionality, but if near-term organic growth disappoints or subsidiary drag extends, the stock has limited downside protection at current levels.
The bull-bear ledger
Volume growth is real and corroborated (85% of 39% from tonnes, not pricing gimmicks)
EBITDA margin expanded 49 bps despite 80% utilization; operating leverage is present
Capex plan crystallized (₹460 Cr total, ₹225–250 Cr FY27, 35% already spent); backward integration de-risks sourcing
Reported PAT includes ₹13 Cr one-time forex gain (16.5% of profit); organic growth ~13% YoY, not 67%
Subsidiary losses (₹3–5 Cr Q1) will suppress consolidated margin 2–3 years; a real drag, not a surprise
Management guided conservatively (no FY27 topline/margin specifics, capacity target 80% vs internal 85–90%); suggests macro caution
Freight/logistics volatility (other expenses +16% YoY) and geopolitical risk (Nigeria shea ban) live; margin cushion is thin
Risks, ranked by severity to a shareholder
Subsidiary ramp-out extends beyond 2–3 year estimate
Medium-HighIf Brazil/Chad scale slower than expected (execution delays, weak demand), consolidated losses persist. A ₹4–5 Cr quarterly drag becomes structural, compressing consolidated margin vs. standalone profit.
Geopolitical supply disruption (Nigeria shea ban; additional country bans)
MediumShea sourced from 22 African countries; while company has 10 subsidiaries and Burkina Faso facility under development, a second ban or logistics shock could spike input costs or constrain volumes materially.
Freight and logistics costs remain elevated
MediumOther expenses jumped 16% YoY (freight/container-driven). Value-added product pricing is stable, not rising; if freight doesn't normalize, gross margin (45–50% band) compresses and flow-through to EBITDA is negative.
New capex commissioning slips (Q3 FY28 is 'tentative')
Low-MediumSolvent fractionation, refinery, and Burkina Faso are all scheduled Q3 FY28. Construction delays common in India/Africa; if slipped to FY29, the 3-year payback extends and full-scale contribution is pushed 12+ months.
Supplier quality recovery fails or is delayed
Low-MediumDebit note raised against unnamed supplier; recovery 'in process' per SEBI disclosure. If claim rejected or timeline extends, company absorbs loss; reputational and financial impact.
The debate: What is this quarter worth?
What to watch next
1 · Q2 organic run-rate and margin without the forex cushion
Without the ₹13 Cr forex boost, Q2 will test underlying quality. If organic PAT is ₹65–70 Cr and EBITDA margin stays 25–26%, the bull case holds. If it dips below 25% or freight/mix pressure shows, the bear case (margin squeeze, subsidiary drag) becomes live.
2 · Capacity utilization ramp and incremental EBITDA margin
Debottlenecking 4.5k MT targeting Q3 FY27. If utilization reaches 85% (vs 80% guidance) with incremental EBITDA margin ≥27%, the capex case strengthens. If it stalls at 80%, the growth story is slower than marketed.
3 · Brazil subsidiary ramp trajectory and consolidated margin bridging
Management guided for 2–3 years of subsidiary losses before scale. H1 FY28 clarity on Brazil revenue and breakeven timeline will determine if consolidated margin can recover to 24%+ by FY29. If delayed, the street will reprice downward.
Manorama delivered a textbook operational quarter—volume growth corroborated, margins stable, capex on track. But reported profit is not as robust as the headline: ₹13 crore in one-time forex gains flatter the PAT by 16%, and near-term subsidiary losses will depress consolidated growth. Management's choice to reiterate rather than raise FY27 guidance, despite the Q1 beat, is the real tell. They are pricing in macro caution and execution timelines the street may be underestimating.
The stock has momentum and the capex story is valid. But at ₹1,901, only -6.95% from all-time high, the risk-reward is balanced. The number to track from here is organic PAT (normalized for one-timers), not reported. If Q2 shows sustainable mid-teens growth with margins stable and subsidiary losses track the forecast, the bull case justifies higher multiples. If subsidiary drag or freight pressure emerges, the stock will re-rate lower. Wait for the next quarterly print before adding here.